(Q36652262)

15 August 2017

1 reference

title

Inflammation and coagulation in inflammatory bowel disease: The clot thickens (English)

1 reference

inflammatory bowel diseases

15 August 2017

main subject

0 references

1

Silvio Danese

1 reference

15 August 2017

Alfredo Papa

2

1 reference

15 August 2017

Simone Saibeni

3

1 reference

15 August 2017

Alessandro Repici

4

1 reference

15 August 2017

Alberto Malesci

5

1 reference

15 August 2017

Maurizio Vecchi

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

13 November 2006

1 reference

The American Journal of Gastroenterology

15 August 2017

published in

1 reference

15 August 2017

volume

102

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

174-186

1 reference

Acute-phase proteins and other systemic responses to inflammation

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Vascular complications of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Cerebral and retinal vascular complications of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Cerebral sinus thrombosis in patients with inflammatory bowel disease: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Large-artery stroke in a young patient with Crohn's disease. Role of vitamin B6 deficiency-induced hyperhomocysteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Acute myocardial infarction in a young woman with severe ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Aortic mural thrombi in patients with inflammatory bowel disease: report of two cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Increased carotid intima-media thickness in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Venous thromboembolism in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Inherited disorders of coagulation appear to protect against inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Therapy insight: Vascular complications in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Inflammatory bowel disease: the role of environmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Thrombosis and inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

21 January 2018

The Protein C Pathway

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Molecular mechanisms of fibrinolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Crosstalk between inflammation and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Evaluation of the hypercoagulable state. Whom to screen, how to test and treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Reduced free protein S levels in patients with inflammatory bowel disease: prevalence, clinical relevance, and role of anti-protein S antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Cellular microparticles: new players in the field of vascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Serum von Willebrand factor levels in patients with inflammatory bowel disease are related to systemic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Review article: inherited thrombophilia in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Val34Leu factor XIII polymorphism in Italian patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Regional manifestations and control of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

The platelet count as a simple measure to distinguish inflammatory bowel disease from infective diarrhoea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Platelets and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Review article: platelets in inflammatory bowel disease--pathogenetic role and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Chemokine and chemokine receptor mRNA expression in human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t-PA and possible implications in thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00943.X

10.1111/J.1572-0241.2006.00943.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference